Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
This NIH/NCI R61 grant funds early-stage, proof-of-concept development of innovative technologies for molecular or cellular characterization of cancer and biospecimen handling; clinical trials are …
- Deadline
- Nov 10, 2026
- Posted
- Jun 3, 2026
- Award amount
- Up to $150,000
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Nov 10, 2026 so you have time to apply.
In plain English
This NIH/NCI R61 grant funds early-stage, proof-of-concept development of innovative technologies for molecular or cellular characterization of cancer and biospecimen handling; clinical trials are not allowed. It is a research grant for universities, research institutions, and similar eligible organizations, and foreign organizations and foreign components are eligible. The award maximum is about $150,000. Eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this grant
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
National Institutes of Health · Amount varies · Due in 17 days
Alcohol Health Services Research (R34 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Alcohol Health Services Research (R01 Clinical Trial Optional)
National Institutes of Health · Up to $500K · Due in 17 days
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
National Institutes of Health · Amount varies · Due in 17 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.